Stockreport

CytoDyn Announces Significantly Improved Response Rate at Higher Dose of PRO 140 in HIV Phase 3 Monotherapy Trial

CYTODYN INC  (CYDY) 
NASDAQ:AMEX Investor Relations: ir.cytodyn.com
PDF Response rate increases from 40% at 350 mg dose to approximately 70% at 525 mgIRB approves monotherapy protocol modified to include 700 mg dosePRO 140 monotherapy, if ap [Read more]